Common Contracts
2 similar Underwriting Agreement contracts by Laboratory Corp of America Holdings
Laboratory Corporation of America Holdings $500,000,000 2.625% Senior Notes Due 2020 $500,000,000 3.200% Senior Notes Due 2022 $1,000,000,000 3.600% Senior Notes Due 2025 $900,000,000 4.700% Senior Notes Due 2045 Underwriting AgreementUnderwriting Agreement • January 30th, 2015 • Laboratory Corp of America Holdings • Services-medical laboratories • New York
Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (“you” or the “Representatives”) are acting as representatives, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture dated as of November 19, 2010 as supplemented by the Seventh Supplemental Indenture to be dated January 30, 2015, the Eighth Supplemental Indenture to be dated January 30, 2015, the Ninth Supplemental Indenture to be dated January 30, 2015 and the Tenth Supplemental Indenture to be dated January 30, 2015 (collectively, the “Indenture”), each between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters named in Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms
Laboratory Corporation of America Holdings $500,000,000 2.20% Senior Notes Due 2017 $500,000,000 3.75% Senior Notes Due 2022 Underwriting AgreementUnderwriting Agreement • August 23rd, 2012 • Laboratory Corp of America Holdings • Services-medical laboratories • New York
Laboratory Corporation of America Holdings, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its notes identified in Schedule I hereto (the “Notes”), to be issued under an indenture dated as of November 19, 2010 as supplemented by the Third Supplemental Indenture and the Fourth Supplemental Indenture to be dated August 23, 2012 (collectively, the “Indenture”), each between the Company and U.S. Bank National Association, as trustee (the “Trustee”). To the extent there are no additional Underwriters named in Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Any reference herein to the Registration Statement, the Base Prospec
